Preoperative Concurrent Radiochemotherapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer.
10.3346/jkms.2006.21.2.229
- Author:
Min Kyu KANG
1
;
Yong Chan AHN
;
Do Hoon LIM
;
Keunchil PARK
;
Joon Oh PARK
;
Young Mog SHIM
;
Jhingook KIM
;
Kwhanmien KIM
Author Information
1. Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. ycahn@smc.samsung.co.kr
- Publication Type:Original Article
- Keywords:
Carcinoma;
Non-Small Cell Lung;
Preoperative;
Radiotherapy;
Drug Therapy;
Surgery
- MeSH:
Treatment Failure;
Time Factors;
Survival Rate;
Prognosis;
Neoplasm Staging;
Middle Aged;
Male;
Lung Neoplasms/mortality/pathology/*therapy;
Humans;
Female;
Disease-Free Survival;
Combined Modality Therapy;
Carcinoma, Non-Small-Cell Lung/mortality/pathology/secondary/*therapy;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use;
Aged;
Adult
- From:Journal of Korean Medical Science
2006;21(2):229-235
- CountryRepublic of Korea
- Language:English
-
Abstract:
This is to examine whether aggressive multimodality therapy improves the treatment outcomes in stage IIIA non-small cell lung cancer (NSCLC). Fifty-three consecutive NSCLC patients with N2 disease, confirmed by mediastinoscopic biopsy, received preoperative thoracic radiation therapy (45 Gy/5 weeks) concurrent with two cycles of oral etoposide and intravenous cisplatin and surgery. Postoperative radiation therapy (PORT, 18 Gy/2 weeks) was optionally recommended for those with the risk factors of loco-regional recurrence based on the surgical and pathological findings. Surgical resection was performed in 38 patients (71.7%), and down-staging was achieved in 19 patients (50%). The median survival period was 27 months in 38 patients who underwent resection, and the rates at 3-yr of overall survival, loco-regional control, distant metastasis-free survival, and disease-free survival were 44.3%, 87.9%, 32.9%, and 29.3%. Significantly favorable factor regarding overall survival was achieving p0/I stage by the multivariate analysis. PORT was successful in reducing locoregional recurrences in patients with the risk factors. Current preoperative concurrent radiochemotherapy and surgery by the authors resulted in comparable survival with other reports, however, further refinement of multimodality approach may be warranted for more effective reduction of distant metastasis.
